Profile data is unavailable for this security.
About the company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
- Revenue in DKK (TTM)309.06bn
- Net income in DKK102.43bn
- Incorporated1931
- Employees68.79k
- LocationNovo Nordisk A/SNovo Alle 1BAGSVAERD 2880DenmarkDNK
- Phone+45 44448888
- Fax+45 44436633
- Websitehttps://www.novonordisk.com/
Mergers & acquisitions
| Acquired company | NOVO B:CPH since announced | Transaction value |
|---|---|---|
| Metsera Inc | -28.92% | 9.68bn |
| Akero Therapeutics Inc | -38.09% | 5.11bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck KGaA | 158.95bn | 22.08bn | 394.27bn | 62.35k | 17.86 | 1.82 | 10.83 | 2.48 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Regeneron Pharmaceuticals Inc | 92.28bn | 29.27bn | 521.48bn | 15.41k | 18.27 | 2.59 | 15.91 | 5.65 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Chugai Pharmaceutical Co Ltd | 51.31bn | 17.70bn | 676.12bn | 7.78k | 37.43 | 8.02 | -- | 13.18 | 263.73 | 263.73 | 764.40 | 1,230.91 | 0.5379 | 1.41 | 3.59 | -- | 18.56 | 19.40 | 21.83 | 23.54 | 71.09 | 66.75 | 34.50 | 31.46 | 3.56 | 583.66 | -- | 40.95 | 7.46 | 9.84 | 12.06 | 15.11 | 12.69 | 17.27 |
| Sanofi SA | 349.10bn | 36.91bn | 727.77bn | 76.49k | 19.83 | 1.35 | 14.10 | 2.08 | 4.03 | 6.36 | 38.11 | 59.11 | 0.3599 | 1.33 | 5.81 | 610,722.60 | 3.95 | 4.87 | 5.10 | 6.07 | 72.07 | 70.15 | 10.99 | 14.05 | 0.7316 | 31.31 | 0.2208 | 77.11 | 5.49 | 4.57 | -10.13 | -16.67 | 11.18 | 5.18 |
| GSK plc | 280.73bn | 49.12bn | 742.48bn | 68.63k | 15.27 | 5.28 | 8.58 | 2.64 | 1.39 | 1.39 | 7.95 | 4.02 | 0.5418 | 1.54 | 4.57 | -- | 10.43 | 7.00 | 16.02 | 10.95 | 72.67 | 71.30 | 19.25 | 15.49 | 0.5416 | 16.90 | 0.5262 | 69.37 | 4.11 | 6.05 | 121.98 | 5.07 | 5.92 | -7.97 |
| Vertex Pharmaceuticals Inc | 77.22bn | 25.43bn | 775.17bn | 6.40k | 30.93 | 6.45 | 28.94 | 10.04 | 15.33 | 15.33 | 46.51 | 73.49 | 0.4982 | 1.14 | 6.55 | 1,875,203.00 | 16.41 | 13.29 | 19.40 | 15.74 | 86.24 | 86.99 | 32.94 | 25.71 | 2.46 | -- | 0.0057 | 0.00 | 8.90 | 14.10 | 838.09 | 7.83 | 10.99 | -- |
| Novo Nordisk A/S | 309.06bn | 102.43bn | 784.81bn | 68.79k | 10.05 | 5.30 | 6.33 | 2.54 | 23.03 | 23.03 | 69.49 | 43.66 | 0.6128 | 1.30 | 4.33 | 4,492,601.00 | 20.31 | 25.03 | 35.60 | 48.23 | 80.98 | 83.95 | 33.14 | 33.96 | 0.5696 | -- | 0.4029 | 50.28 | 6.43 | 19.48 | 1.43 | 19.44 | 32.48 | 20.79 |
| Bristol-Myers Squibb Co | 310.08bn | 45.39bn | 802.15bn | 32.50k | 17.70 | 6.67 | 11.27 | 2.59 | 3.46 | 3.46 | 23.64 | 9.18 | 0.5278 | 5.03 | 5.02 | 1,482,892.00 | 7.73 | 3.92 | 10.43 | 5.05 | 72.63 | 76.32 | 14.64 | 8.34 | 1.14 | 16.84 | 0.7091 | 122.54 | -0.2195 | 2.54 | 178.83 | -- | 11.73 | 0.658 |
| Pfizer Inc | 402.63bn | 49.83bn | 972.44bn | 75.00k | 19.61 | 1.75 | 10.51 | 2.42 | 1.36 | 1.36 | 10.97 | 15.21 | 0.2969 | 1.41 | 5.36 | 834,386.70 | 3.69 | 7.19 | 4.57 | 9.08 | 75.81 | 69.03 | 12.44 | 19.52 | 0.8718 | 9.40 | 0.4275 | 64.91 | -1.65 | 8.48 | -3.42 | 3.16 | -1.19 | 2.50 |
| Gilead Sciences Inc | 189.44bn | 54.75bn | 1.18tn | 17.00k | 21.79 | 8.08 | 16.28 | 6.23 | 6.78 | 6.78 | 23.46 | 18.29 | 0.499 | 3.58 | 6.31 | 1,731,941.00 | 14.42 | 8.03 | 18.04 | 9.82 | 78.83 | 78.01 | 28.91 | 18.13 | 1.40 | 52.77 | 0.5244 | 74.82 | 2.40 | 3.58 | 1,672.92 | 133.35 | -2.83 | 3.04 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 123.80m | 3.65% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 80.70m | 2.38% |
| Capital International Ltd.as of 05 Feb 2026 | 70.26m | 2.07% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 61.49m | 1.81% |
| Geode Capital Management LLCas of 26 Feb 2026 | 38.96m | 1.15% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 32.24m | 0.95% |
| Capital Research & Management Co. (World Investors)as of 05 Feb 2026 | 30.89m | 0.91% |
| Fundsmith LLPas of 06 Feb 2026 | 24.08m | 0.71% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 21.71m | 0.64% |
| Amundi Asset Management SASU (Investment Management)as of 25 Feb 2026 | 19.32m | 0.57% |
